View Clinical Trial (Medical Research Study)
Pathways Linking Late-Life Depression to MCI & Dementia
| City: |
|
Pittsburgh |
| State: |
|
Pennsylvania |
| Zip Code: |
|
15213 |
| Conditions: |
|
Late-Life Depression |
| Purpose: |
|
This study will determine the changes in brain structure and function that are responsible
for mood and cognition changes that are sometimes associated with late-life depression.
|
| Study Summary: |
|
The goal of this research study is to investigate the relationships among late-life
depression (LLD), cognitive impairment and progressive neurodegeneration. The guiding
hypothesis is that LLD patients have evolving cognitive impairments as a consequence of
distinct underlying neuropathological changes, which frequently are expressed as Mild
Cognitive Impairment (MCI). These neuropathological and cognitive changes are risk
modifiers, lowering brain reserve capacity, and in turn, increasing risk of developing
Alzheimer's Disease (AD). In order to pursue this goal we will enroll LLD, MCI, and normal
control subjects to enrich our existing cohort to include a total of 150 elderly,
non-demented, non-depressed subjects, 60 non-depressed MCI subjects and 270 LLD subjects.
Using the joint infrastructure of the University of Pittsburgh's Advanced Center for
Intervention and Services Research for Late-Life Mood Disorders and the Alzheimer's Disease
Research Center, we will complete a detailed neurobehavioral evaluation, including clinical,
neuropsychological, neuroimaging and biological markers, using these data to evaluate the
factors associated with the development of MCI or dementia. Subjects will be studied
annually for at least three years, allowing us to use longitudinal data to evaluate a series
of linked hypotheses that postulate the pathways by which elderly, depressed patients
develop cognitive impairment, and which may lead some to develop dementia.
|
| Criteria: |
|
Inclusion Criteria:
- Diagnosis of a mood disorder
Exclusion Criteria:
- Major acute medical illnesses or injuries known to have significant direct effects on
cognitive functioning (e.g., metastatic cancer, multiple sclerosis, traumatic brain
injury).
- Uncorrectable sensory handicap (e.g., blindness), because they are unable to complete
the cognitive test battery.
- Exclusion criteria for MR scans include: cardiac pacemaker, aneurysm clip, cochlear
implant, pregnancy, IUD, shrapnel, history of metal fragments in the eye,
neurostimulators, weight of 250 lbs. or more, or claustrophobia.
|
| NCT ID: |
|
NCT00178087 |
| Primary Contact: |
|
Principal Investigator
Meryl A. Butters, Ph.D.
University of Pittsburgh
Meryl A. Butters, Ph.D.
Phone: 412-246-5280
Email: buttersma@upmc.edu
|
| Backup Contact: |
|
Email: zmudamd@upmc.edu
Michelle D. Zmuda, B.S.
Phone: 412-246-6487
|
| Location Contact: |
|
Pittsburgh, Pennsylvania 15213
United States
Jacqueline A. Stack, MSN,RN,CSN
Phone: 412-246-6006
Email: stackja@upmc.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 19, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|